Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.61 |
| ▸ | CTSS | P25774 | 8/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17369162 | 1.00 | CTSK (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16379313 | 1.00 | CTSK (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18130977 | 0.91 | CTSK (0.60) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5040904 | 0.91 | CTSK (0.60) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18082612 | 0.91 | CTSK (0.60) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29508434 | 0.90 | CYP1A2 (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17614512 | 0.90 | CTSK (0.67) | CTSKCTSS | |
| SCHEMBL13560958 | 0.90 | CYP1A2 (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14483921 | 0.90 | CYP1A2 (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17369166 | 0.88 | CTSK (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840457-B2 | Lysine isotopologues, compositions comprising the same and methods of synthesis | CAMBRIDGE ISOTOPE LABORATORIES, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160016890-A1 | LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS | CAMBRIDGE ISOTOPE LABORATORIES, INC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016890-A1 | LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS | PLOD1, PHYKPL, AADAT | CTSK 785/4885CTSS 2046/4885CYP1A2 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.